All In Biotech

NDA 210192 · Viiv Hlthcare

Juluca

Dolutegravir Sodium, Rilpivirine Hydrochloride · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 21, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

306

91 Phase 3, 30 recruiting

FAERS reports

1,764

926 serious, 98 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2025.

JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA, a two-drug combination of dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. ( 1 )

Mechanism: JULUCA is a fixed-dose combination of the HIV-1 antiretroviral agents, dolutegravir and rilpivirine [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • JULUCA · DOLUTEGRAVIR SODIUM EQ 50MG BASE; RILPIVIRINE HYDROCHLORIDE EQ 25MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dolutegravir" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain312
  • product dose omission issue296
  • anxiety285
  • emotional distress278
  • anhedonia251
  • chronic kidney disease204
  • renal failure132
  • fatigue125
  • depression120
  • osteoporosis92
  • acute kidney injury88
  • economic problem84

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20164
20171
2018153
2019263
2020218
2021171
2022240
2023247
2024218
2025189
202660

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Juluca (Dolutegravir/Rilpivirine)

2024 spending

$415M

Beneficiaries

12,112

112,878 claims

Per beneficiary

$34,282

$116.11 per unit

View as table
YearSpending
2020$252,273,517
2021$298,134,488
2022$346,740,919
2023$392,257,065
2024$415,220,185

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 435 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.